Clinical Drug–Drug Interaction Potential of BFE1224, Prodrug of Antifungal Ravuconazole, Using Two Types of Cocktails in Healthy Subjects

BFE1224, prodrug of ravuconazole, is a novel, once‐daily, oral, triazole antifungal drug, and currently in development for the treatment of onychomycosis. The clinical drug–drug interaction (DDI) potential of BFE1224 with cytochrome P450 (CYP) and transporter was assessed by using two types of cockt...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishii, Yasuyuki, Ito, Yuko, Matsuki, Shunji, Sanpei, Kasumi, Ogawa, Osamu, Takeda, Kenji, Schuck, Edgar L., Uemura, Naoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132366/
https://www.ncbi.nlm.nih.gov/pubmed/29768713
http://dx.doi.org/10.1111/cts.12557

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132366/
https://www.ncbi.nlm.nih.gov/pubmed/29768713
http://dx.doi.org/10.1111/cts.12557

Ejemplares similares